nilotinib: Clinical Trials

32 trials of nilotinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

18 completed, 7 terminated, 3 unknown, 2 active not recruiting. 32 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 332Completed 18, Terminated 7, Unknown 3, Active not recruiting 2, Not yet recruiting 2
Phase 21Completed 1

Follow nilotinib: new trials by email Literature Review of nilotinib trials Research Report on nilotinib

Trials (filtered) newest first · largest first

All 32 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Randomized Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs
ELVN-001, TKI - Chronic Myeloid Leukemia (CML), Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
Phase 3Not yet recruitingEnliven Therapeutics4502026-12-312026-10-29
A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
HS-10382, Imatinib, Dasatinib - Chronic Myeloid Leukemia
Phase 3Not yet recruitingJiangsu Hansoh Pharmaceutical Co., Ltd.4082026-12-012026-10-21
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
Asciminib, Nilotinib - Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Phase 3Active not recruitingNovartis Pharmaceuticals5682022-11-212026-08-26
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Imatinib, Nilotinib, Bosutinib - Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
Phase 3Active not recruitingNovartis Pharmaceuticals4052021-10-062026-08-28
Molecular Profiling of Advanced Soft-tissue Sarcomas
Nilotinib, Ceritinib, Capmatinib - Soft Tissue Sarcoma
Phase 3CompletedInstitut National de la Santé Et de la Recherche Médicale, France6032019-10-192026-04-29
Nilotinib for First-line Newly Diagnosed CML-CP Patients
Nilotinib - Chronic Myeloid Leukemia, Chronic Phase, Nilotinib
Phase 3UnknownShenzhen Second People's Hospital1002019-06-012022-03-16
Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid Leukemia
Dasatinib 100 MG [Sprycel], Nilotinib 150mg oral capsule [Tasigna] - Chronic Myeloid Leukemia - Chronic Phase
Phase 3TerminatedHamad Medical Corporation102017-08-032019-01-23
A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults
Nilotinib, Methotrexate, Aracytine (Ara C) - Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia
Phase 3UnknownAssistance Publique - Hôpitaux de Paris2652016-04-012019-10-21
A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia
Ponatinib 30 mg QD, Ponatinib 15 mg QD, Nilotinib 400 mg BID - Chronic Phase Chronic Myeloid Leukemia
Phase 3TerminatedAriad Pharmaceuticals442015-12-312021-11-26
Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib
Nilotinib - Philadelphia Positive (Ph+) Chronic Myeloid Leukemia
Phase 3TerminatedNovartis Pharmaceuticals72015-12-172019-12-10
Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response
imatinib, nilotinib, dasatinib - Leukemia, Chronic Myeloid
Phase 3CompletedAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia2292015-06-102024-08-13
Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients
Nilotinib (Tasigna ®), capsules of 150 mg, Nilotinib (Tasigna ®) and Pegylated interferon alfa 2a (Pegasys®) - Chronic Myeloid Leukemia
Phase 3CompletedHospices Civils de Lyon2002014-08-012025-10-02
A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase
Imatinib, Nilotinib - Leukemia
Phase 3CompletedNovartis Pharmaceuticals2252014-07-172019-08-19
Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.
Nilotinib - Philidelphia Positive Chronic Myeloid Leukaemia
Phase 3TerminatedNovartis Pharmaceuticals202014-07-072017-10-27
An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years
Imatinib, Nilotinib - Chronic Myeloid Leukemia
Phase 3TerminatedProf. Dr. Nikolas von Bubnoff142014-03-012019-12-02
A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.
Nilotinib - Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Phase 3CompletedNovartis Pharmaceuticals6202013-04-152021-07-15
Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance
Imatinib and Nilotinib - Leukemia, Myeloid, Chronic, BCR-ABL Positive
Phase 3CompletedHospital Universitario Dr. Jose E. Gonzalez102012-10-012014-01-07
TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study
Peginterferon α2b, Nilotinib - Chronic Myeloid Leukemia
Phase 3CompletedUniversity of Jena7172012-08-242023-05-10
Nilotinib in PH+, BCR-, ABL+ CML Patients
Nilotinib - Chronic Myeloid Leukemia
Phase 3CompletedGruppo Italiano Malattie EMatologiche dell'Adulto1092012-01-012018-08-06
Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients
Nilotinib - Chronic Myeloid Leukemia
Phase 3CompletedNovartis Pharmaceuticals4212011-04-012016-03-03

Showing 20 of 32. Sign in to see all of them.

Conditions studied

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (24)  ·  Leukemia (9)  ·  Gastrointestinal Stromal Tumors (4)  ·  Leukemia, Myeloid, Chronic-Phase (4)  ·  Philadelphia Chromosome (4)  ·  Bone Marrow Diseases (3)  ·  Leukemia, Myeloid (3)  ·  Bronchiolitis Obliterans Syndrome (2)  ·  Hematologic Neoplasms (2)  ·  Myeloproliferative Disorders (2)  ·  Neoplasms (2)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (2)  ·  Hematologic Diseases (1)  ·  Neoplasm Metastasis (1)  ·  Neoplasms by Histologic Type (1)

Sponsors

Novartis Pharmaceuticals (18)  ·  Ariad Pharmaceuticals (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (1)  ·  Enliven Therapeutics (1)  ·  Gruppo Italiano Malattie EMatologiche dell'Adulto (1)  ·  Hamad Medical Corporation (1)  ·  Hospices Civils de Lyon (1)  ·  Hospital Universitario Dr. Jose E. Gonzalez (1)  ·  Institut National de la Santé Et de la Recherche Médicale, France (1)  ·  Jiangsu Hansoh Pharmaceutical Co., Ltd. (1)  ·  Prof. Dr. Nikolas von Bubnoff (1)  ·  Seoul St. Mary's Hospital (1)  ·  Shenzhen Second People's Hospital (1)  ·  University of Jena (1)

Countries

Germany (11)  ·  France (10)  ·  Italy (10)  ·  Canada (8)  ·  China (8)  ·  Czechia (8)  ·  South Korea (8)  ·  Argentina (7)  ·  Brazil (7)  ·  Spain (7)  ·  Australia (6)  ·  Mexico (6)  ·  Russia (6)  ·  United States (6)  ·  Austria (5)

Top investigators

Andreas Hochhaus, Prof. MD (1)  ·  Antoine Italiano (1)  ·  Domenico Russo, Professor (1)  ·  Dong-Wook Kim, MD, PhD (1)  ·  Gianantonio Rosti (1)  ·  Mohamed A Yassin (1)  ·  Nikolas von Bubnoff, Professor (1)

Results publications

PMID 17715389, PMID 20525993, PMID 21467546, PMID 21856226, PMID 22207416, PMID 23109697, PMID 23502220, PMID 24335106, PMID 24472814, PMID 24532039, PMID 24948656, PMID 25766724, PMID 25882987, PMID 26871197, PMID 27470600, PMID 27890073, PMID 28699641, PMID 32713836, PMID 34123791, PMID 34740331, PMID 36524980, PMID 38452207, PMID 38820078, PMID 41397287, PMID 42069411, PMID 42339511

NIH funding

2008 (3), 2009 (1), 2015 (1), 2017 (1), 2023 (1)